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A b s t r A c t
Menopause and the climacteric period are associated with adverse risk factors for the development of vulvovaginal atrophy‑ 
related sexual dysfunction. Sexual dysfunction is a common problem in postmenopausal women, often underdiagnosed, 
inadequately treated, frequently overlooked, and most often impairing the quality of life of these women. To provide clinicians 
with current information on vulvovaginal atrophy‑related sexual dysfunction in postmenopausal women. This study is a 
literature review on vulvovaginal atrophy‑related sexual dysfunction in postmenopausal women. Relevant publications were 
identified through a search of PubMed and Medline, selected references, journals, and textbooks on this topic, and were 
included in the review. The prevalence of female sexual dysfunction increases with age. It is a common multidimensional 
problem for postmenopausal women that alter the physiological, biochemical, psychological, and sociocultural environment of 
a woman. Menopause‑related sexual dysfunction may not be reversible without therapy. Estrogen therapy is the most effective 
option and is the current standard of care for vulvovaginal atrophy‑related sexual dysfunction in postmenopausal women. 
Sexual dysfunction is a common multidimensional problem for postmenopausal women and often impairs the quality of life 
of these women. Estrogen preparations are the most effective treatment. Selective estrogen receptor modulators, vaginal 
dehydroepiandrostenedione, vaginal testosterone, and tissue‑selective estrogen complexes are promising therapies, but 
further studies are required to confirm their role, efficacy, and safety.
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Sexual dysfunction is the persistent or recurrent inability 
to attain or maintain adequate genital lubrication or sexual 
responses, resulting in personal distress. Sexual dysfunction 
may involve a reduction in sex drive, a strong dislike of 
sexual activity, difficulty becoming aroused, inability to 
achieve orgasm, or pain with sexual activity or intercourse. 
Female sexual dysfunction is classified basically into four 
kinds of sexual problems such as desire disorders, arousal 
disorders, orgasmic disorders, and sexual pain disorders. 
Traditionally, sexual dysfunction in women was thought 
to be largely due to psychological problems. Recently, 
researchers are beginning to uncover many physical causes 
for sexual problems in women. Although many sexual 
problems have an underlying psychological component, 
possible physical causes must be ruled out in the initial 
examination. Perimenopause and menopause transition is a 
time when changes inevitably occur, making female sexual 
dysfunction very common in this age group.
Sexual dysfunction is a known problem for postmenopausal 
women. Menopause alters the physiological, biochemical, 
psychological, and sociocultural environment of a woman.[1] 
Thus, the knowledge and perception of its symptomatology 
is invaluable to enable appropriate adjustment to this 
natural phenomenon.[1,2] These changes, if not adjusted, 
may have a negative impact on sexual function. The vast 
majority of women reach menopause and spend one-third 
of their lives in this state.[3] Menopause is recognized with 
certainty only in retrospect after 12 months of amenorrhea 
without obvious pathologic or physiological cause.[4] 
An  adequate independent biologic marker for this event 
does not exist.[4]
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The prevalence of female sexual dysfunction increases 
with age, and the majority of women older than 60 years 
present with sexual inactivity, difficulty with intercourse, or 
dyspareunia.[5] Estrogen deficiency can affect other aspects 
of sexual function, including reduced vaginal blood flow 
and a reduced capacity for arousal and orgasm.
In postmenopausal women, genital arousal may be reduced 
and sexual pain disorders may occur as a result of the 
hypoestrogenic state.[6] There is a common presentation in 
postmenopausal women of a lack of mental arousal and a 
decline of sexual desire after a history of sexual pain, which 
can lead to the reduction of orgasmic capacity and sexual 
satisfaction.[2] These problems may influence sexual desire, 
activity, and the relationship of the couple negatively. Thus, 
it may be necessary to avoid such negative events by treating 
sexual dysfunction during menopause.[1,2] The aim of this 
review was to provide clinicians with current information 
on vulvovaginal atrophy-related sexual dysfunction in 
postmenopausal women.
MeTHODOLOGY
We reviewed pertinent literature on vulvovaginal 
atrophy-related sexual dysfunction in postmenopausal 
women, and selected references and internet material using 
the PubMed and Medline databases for relevant publications 
in journals and textbooks on this topic.
Pathophysiology
During climacteric, there is cessation of ovarian activity 
and a fall in the estrogen level with a rebound increase in 
the secretion of the follicle-stimulating hormone (FSH) by 
the anterior pituitary gland. The serum estradiol level is 
30-300 pg/mL in the reproductive-aged woman depending 
on the phase of the menstrual cycle.[2] In postmenopausal 
women,	this	level	is	decreased	by	more	than	90%	to	a	mean	
of 6.5 pg/mL.[7] The principal estrogen in postmenopausal 
women	 is	 estrone,	 which	 also	 decreases	 by	 70%	 after	
menopause.[8] Estrone is derived mainly from peripheral 
aromatization of androstenedione.[3] It is the lack of 
estrogen that causes the majority of the symptoms and 
pathology of menopause. Estrogen receptors are expressed 
in the vulvovaginal and urogenital mucosa during the 
reproductive years of a woman. These receptors are 
responsible for mediating biochemical and physiologic 
functions. With the loss of estrogen stimulation, changes 
occur within the vulvovaginal and urogenital mucosa. There 
is a characteristics loss of vaginal rugae and shortening 
and narrowing of the vagina. The thick vaginal epithelium 
transforms into a pale, dry, thin vaginal epithelium that 
is more prone to inflammation.[9] Vulvovaginal atrophy is 
characterized by a smooth and shiny appearance of the 
vagina and patchy erythema with increased friability. The 
collagen fibers fuse and undergo hyalinization while the 
elastin fibers fragment. There is an overall loss of mucosal 
elasticity.[9] During menopause, there is loss of vascular 
support and reduced vaginal secretions with loss of vaginal 
transudate. There is an equally reduced cervical mucus and 
the number of epithelial cells reduce with advancing age.[10] 
The resultant decreased vaginal secretions and the delay in 
vaginal lubrication during sexual intercourse contributes 
significantly to dyspareunia in postmenopausal women. 
Reduced levels of estrogen cause urogenital atrophy and 
urogenital diaphragm weakness. The atrophic changes in 
the female lower genital tract lead to symptoms of dysuria, 
urethral discomfort, and stress incontinence.[11]
Risk factors
The risk factors for menopause-related diseases are 
premature menopause, surgical menopause, radiation, 
chemotherapy, especially alkylating agents, smoking, 
caffeine, alcohol, family history of menopausal diseases, 
heparin, corticosteroids, and clomiphene given over a 
prolonged period (over 6 months) leading to estrogen 
deficiency.[8]
Anatomical changes
The genital organs undergo atrophy and retrogression. 
The uterus becomes smaller as a result of atrophy of the 
muscles of the body and fundus. The connective tissues 
are more conspicuous. The endometrium is represented by 
only the basal layer with its compact deeply stained stroma 
and a few simple tubular glands. The lymphoid tissue and 
functional layer disappear.
The cervix becomes smaller, and its vaginal portion is 
represented by a small prominence at the vaginal vaults. The 
vaginal fornices gradually disappear as the cervix shrinks 
after menopause. Erosions, ectropions, and ulcers are seen 
more commonly in postmenopausal women.[12] Secretion of 
endocervical glandular mucin is reduced markedly, leading 
to vaginal dryness. The squamocolumnar junction and 
transformation zone migrate high into the endocervical 
canal. This often renders colposcopic assessment difficult.[12]
The vagina becomes narrow, and its epithelium becomes 
pale, thin, and dry and gets easily infected causing senile 
vaginitis. The vulva atrophies and the vaginal orifice 
narrows, and this can cause dyspareunia. The skin of the 
labia minora and vestibule becomes thin, pale, and dry, 
and there is considerable reduction in the amount of 
fat contained in the labia majora. Vulvovaginal atrophy 
often leads to vaginal dryness, itching, irritation, reduced 
lubrication, dyspareunia, and vaginal bleeding associated 
with sexual activity.[11]
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The pubic hair is reduced and becomes grey. The red 
patches seen around the urethra and introitus are caused by 
senile vulvitis, and a urethral caruncule may be produced. 
The pelvic cellular tissue becomes lax and the ligaments 
that support the uterus and vagina lose their tone and 

















Stress incontinence and urge incontinence
Dry vagina




•	 Narrowing	 of	 the	 introitus	 and	 inflamed	 mucosal	
surfaces









•	 The	 first	 step	 in	 the	 diagnosis	 is	 a	 thorough	 history	
taking, general examination including recording of 
blood pressure, breast palpation, weight, hirsutism, 
and gynecologic examination
•	 Pelvic	examination:	External	genitalia	for	signs	of	vulval	
atrophy and vulval lesions
•	 Pap	smear	and	a	vaginal	swab	for	microscopy,	culture,	
and sensitivity
•	 Vaginal	 scraping	 for	 vaginal	 maturation	 index	 (this	
index consists of the percentages of the parabasal, 
intermediate, and superficial squamous cells noted on 
a cytologic smear of cells from the upper one-third of 
the vagina and provides a means of evaluating chronic 
hormonal influence on the vaginal vault). An atrophic 
pattern shows the predominance of parabasal cells, 
whereas estrogen stimulates the development of 
superficial squamous cells[14]
•	 Measurement	 of	 vaginal	 pH:	 Hormonal	 influence	 can	
also be effectively measured by moistening a pH test 






•	 Bone	 density	 test	 (courtesy	 of	Mayo	Clinic	 products	
and services): This is used to identify decreases in 
density, determine the risk of fractures, confirm 
a diagnosis of osteoporosis, and finally monitor 
treatment for osteoporosis. A bone density test uses 
X-rays to measure the quantity (g) of calcium and 
other bone minerals that are packed into a segment of 
bone. The bones that are most commonly tested are 
located in the spine, hip, and forearm. Bone density 
test results are reported in two measures: T-score and 
Z-score.
T-score is your bone density compared with what is normally 
expected in a healthy young adult of your sex. Your T-score 
is the number of units called standard deviations that your 
bone density is above or below the average.
Normal bone density is indicated by a score of −1 and above. 
A score between −1 and −2.5 is a sign of osteopenia (bone 
density is below normal and may lead to osteoporosis). 
A score of −2.5 and below density indicates osteoporosis.
Z-score is the number of standard deviations above or below 
what is normally expected for someone of your age, sex, 
and ethnic or racial origin. If your Z-score is −2 or lower, 
it may suggest that something other than aging is causing 
abnormal bone loss.
Associations of medical conditions with sexual 
dysfunction
Some medical conditions are associated with sexual 
dysfunction and must be evaluated before treatment with 
medications. These medical conditions are diabetes mellitus, 
hypercholesterolemia, hypertension, cardiovascular 
disease, neurologic disease, psychiatric disorders, and 
genitourinary disease. Certain non-neoplastic conditions 
such as squamous hyperplasia, contact dermatitis, and 
lichen sclerosis present with symptoms as seen in atrophic 
vulvovaginitis. These conditions require tissue biopsies to 
make a definitive diagnosis.
Okeke, et al.: Postmenopausal vulvovaginal atrophy‑related sexual dysfunction
Journal of Basic and Clinical Reproductive Sciences · January - December 2012 · Vol 1 · Issue 1 and 26
Treatment of vulvovaginal atrophy‑related 
sexual dysfunction in postmenopausal women
The aim of treating vulvovaginal atrophy is to relieve 
symptoms and to reverse anatomical changes that may 
have effects on other dimensions of sexual function that 
result from decreased estrogen levels.[11] Estrogen therapy 
is the most effective option and is the current standard of 
care for vulvovaginal atrophy. Estrogen therapy is good 
and a logical treatment option in this population for 
atrophy-related symptoms like dryness, irritation, pruritus, 
urinary urgency, and dyspareunia by restoring normal 
vaginal pH levels and thickening and revascularizing 
the epithelium.[11,16] Intravaginal estrogen therapy in 
postmenopausal women is effective in relieving symptoms 
of urogenital atrophy and in improving sexual functions 
and urinary incontinence.[17] Local estrogens for the 
treatment of vaginal atrophy are estradiol and conjugated 
estrogens and in a variety of formulations for vaginal use 
such as creams, tablets, and hormone-releasing rings.[18,19] 
Local estrogen has been shown to decrease vulvovaginal 
atrophy-related dyspareunia in postmenopausal 
women. [19] Local estrogen therapy may improve sexual 
desire, arousal, and orgasmic function by increasing blood 
flow to the urogenital region and by increasing vaginal 
lubrication and oxygen levels.[20] Therapy for atrophic 
vaginitis requires the use of low-dose estrogen therapy.
Risks associated with vaginal estrogen therapy
Vaginal estrogen preparations yield low levels of circulating 
estrogens, but there is risk of endometrial hyperplasia in 
users who have not had a hysterectomy.[21]
Selective estrogen receptor modulators
Both raloxifene and tamoxifen do not have a beneficial 
or detrimental effect on vaginal tissue and on symptoms 
of vulvovaginal atrophy.[22] They are commonly used in the 
treatment of osteoporosis and chemoprophylaxis/treatment 
of breast cancer, respectively. Lasofoxifene and ospemifene 
have a positive impact on vaginal tissue in postmenopausal 
women but have not been approved by the Food and Drug 
Administration (FDA).
Other promising new therapies are vaginal 
dehydroepiandrosterone (DHEA),[23,24] vaginal testosterone, 
and tissue-selective estrogen complexes (TSECs), but 
further studies are required to confirm their efficiency and 
safety.[21,24,25]
Nonhormonal treatment
Vaginal lubricants and moisturizers are alternative choices 
to vaginal estrogens for the treatment of vulvovaginal 
atrophy-related sexual dysfunction.[26] They can be safely 
used by women who do not want to use hormonal therapy.
Moisturizers are used to replace normal vaginal secretions, 
whereas lubricants are designed to reduce friction 
associated with sexual activity.[27] There are two basic 
lubricant formulations, water-based and silicone-based 
products. Water-based lubricants are commoner; 
water-based lubricants include K-Y jelly, Astroglide, and 
Slippery Stuff Gel. They are applied to the vaginal introitus 
before intercourse. Vaginal moisturizers include Replens, 
K-Y Liquibeads, RepHresh, and Emerita. The commonly used 
vaginal moisturizer is Replens. Replens is an effective therapy 
for improving vaginal moisture, vaginal fluid volume, pH, 
and vaginal elasticity, and for reducing symptoms of itching, 
irritation, and dyspareunia.[28]
Alternative therapies
Alternative therapies such as acupuncture, plant estrogens, 
herbal supplements, soy, chasteberry, and ginseng are 
popular among postmenopausal women; however, data 
are limited, and they have not been adequately studied 
for the treatment of vulvovaginal atrophy.[29] These agents 
cannot be recommended as treatment of vulvovaginal 
atrophy-related symptoms as their sources, doses, and 
efficiency are poorly documented.[30] Vitamin D and dietary 
supplementation with a soy-based product (a source of 
phytoestrogen) are used by postmenopausal women, but 
they have not been studied sufficiently for the treatment of 
vulvovaginal atrophy.[31]
Induction of menopause with chemotherapy in 
breast cancer patients
A good number of women with breast cancer have some 
sexual dysfunction after treatment of the cancer.[32,33] 
Surgical treatment of breast cancer results in deprivation 
of estrogen and the onset of menopausal symptoms, which 
affect sexual function negatively.[17,34] Women who survive 
breast cancer after treatment have a high prevalence of 
severe postmenopausal symptoms because of the induction 
of a premature menopause with chemotherapy.[17,34] This 
results in a profound deprivation of estrogen.[35] Aromatase 
inhibitors (AIs) have been shown to disrupt sexual 
function.[36] With the increasing use of AIs, the number of 
women who present with symptomatic atrophic vaginitis 
after treatment for breast cancer is likely to increase.[37] As 
there is greater incidence of vaginal atrophy in women taking 
AIs, a safe and effective non-estrogen therapy is necessary. 
Low-dose vaginal estrogen therapies were effective for 
relieving urogenital atrophy in survivors of breast cancer, 
whereas nonhormonal moisturizers only provided transient 
benefit.[38] A patient with a history of breast cancer can use 
less effective vaginal moisturizers or lubricants if she does 
not want to use vaginal estrogen preparations.[17,27,38]
Psychosocial issues in postmenopausal women
The association between many psychological factors 
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and sexual dysfunction may be bidirectional in terms of 
causation;[39] however, studies have demonstrated strong 
correlations between psychosocial factors and the prevalence 
of sexual dysfunction in women.[39] Furthermore, treatment 
with certain antidepressants increases the risk of sexual 
dysfunction. Psychosocial issues result in both positive and 
negative perceptions of menopause-associated changes. 
The changes are concerns about body image and increased 
changes in the body (wrinkles, body shape/weight, loss of 
muscle tone), loss of sexual self-confidence or performance 
anxiety, diminished affection for or attraction to partner, 
affective disorders (depression, anxiety), distress (personal, 
emotional, occupational, sexual), fulfillment of life goals (or 
lack of fulfillment). Other psychosocial issues are positive 
perception of menopause such as an increased sense of 
freedom from fear of pregnancy, from menstruation, from 
childcare responsibilities, and freedom to concentrate on 
one’s own needs.[40]
Aging and menopause are associated with significant changes 
in body image that are driven by weight gain, changes in body 
shape, changes in career, stresses such as reduced attention 
and care for elderly parents, changes in facial appearance, and 
low self-esteem with other health issues such as uterovaginal 
prolapse and incontinence. These may lead to an extended 
period of grief over lost youth and beauty with an increased 
risk of anxiety and depression. The partner is undergoing 
changes of aging equally and may no longer elicit the same 
degree of sexual attraction from the woman.
Partner issues and relationship dynamics are contributors 
to sexual dysfunction. The availability of a partner can be a 
problem for aging women, because of divorce, separation 
in marriage, death or chronic illness of partner, sexual 
dysfunction of partner, or extramarital affairs.[41] Frequent 
problems may be a result of poor communication in terms 
of changes related to aging in both women and their 
partners. Both partners are likely to undergo decreased 
sexual responsiveness with aging, which can lead to 
performance anxiety.[39,41-43] Partner relationships of long 
duration may undergo a gradual diminution of sexual 
frequency. In case of infidelity on the part of the partner, 
it can lead to withdrawal, anger, rage, or disaffection and 
ultimately to ‘sexual retirement.’[39] Attenuated sexual desire 
in postmenopausal women is associated with low levels of 
satisfaction from the relationship, increased distress, and 
low frequency of sexual activity.[39,41,44]
cOncLUsIOn
Menopause is associated with various endocrine changes, 
which bring about female sexual dysfunction. The following 
complaints are common in postmenopausal women such 
as vaginal dryness, dyspareunia, decreased libido, and 
poor sexual satisfaction. These complaints are prominent 
in women with premature menopause.[45] Low-dose local 
vaginal estrogen is effective and well tolerated in treating 
vulvovaginal atrophy-related sexual dysfunction.[46-48] 
Women with a history of breast cancer and severe vaginal 
atrophy-related dyspareunia and ineffective nonhormonal 
therapies could be offered vaginal estrogen preparations 
with the lowest systemic absorption rate.[49] Women who 
wish to avoid the use of hormone therapy could be offered 
vaginal lubricants and moisturizers applied on a regular 
basis.[50] Data are limited on SERMs,[51] TSECs,[52-54] vaginal 
DHEA,[55] and vaginal testosterone,[56] but they showed 
a positive impact on vaginal tissue in postmenopausal 
women; however, further studies are needed to confirm 
their efficacy and safety.[23,57]
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